Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.32 |
| ▸ | RAPGEF3 | O95398 | 2/20 | 0.30 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30899498 | 0.88 | PARP10 (0.33) | PARP10PARP11KDM1AKCNH2KDM1B | |
| SCHEMBL31649773 | 0.86 | PARP10 (0.33) | PARP10PARP11KDM1AKCNH2KDM1B | |
| SCHEMBL31649702 | 0.76 | HTR2A (0.39) | PARP10PARP11 | |
| SCHEMBL31393728 | 0.73 | PARP10 (0.42) | PARP10PARP11 | |
| SCHEMBL31076283 | 0.73 | ALDH1A1 (0.36) | — | |
| SCHEMBL20865736 | 0.72 | ALDH1A1 (0.38) | PARP10PARP11 | |
| SCHEMBL619582 | 0.72 | PARP10 (0.37) | PARP10PARP11 | |
| SCHEMBL15278369 | 0.71 | — | — | |
| SCHEMBL7985965 | 0.69 | CRBN (0.30) | — | |
| SCHEMBL23384836 | 0.68 | NOTUM (0.46) | PARP10PARP11KDM1AKCNH2KDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3702354-B1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | HAIHE BIOPHARMA CO LTD (CN) | 2024-05-22 | — | — | EP | disclosed |
| US-11465984-B2 | Compound having ERK kinase inhibitory activity and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2022-10-11 | — | — | US | disclosed |
| EP-3702354-A1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | Shanghai Haihe Pharmaceutical Co., Ltd. (CN) | 2020-09-02 | — | — | EP | disclosed |
| EP-3702354-A1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | Shanghai Haihe Pharmaceutical Co., Ltd. (CN) | 2020-09-02 | — | — | EP | disclosed |
| US-20200247781-A1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | HAIHE BIOPHARMA CO., LTD. (CN) | 2020-08-06 | — | — | US | disclosed |
| US-20200247781-A1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | HAIHE BIOPHARMA CO., LTD. (CN) | 2020-08-06 | — | — | US | disclosed |
| WO-2019062949-A1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | 上海海和药物研究开发有限公司 | 2019-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11465984-B2 | Compound having ERK kinase inhibitory activity and use thereof | MAPK1, MAPK4, MAPK7 | PARP10 2202/4885PARP11 1785/4885KDM1A 2507/4885 |
| US-20200247781-A1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | MAPK1, MAPK4, MAPK7 | PARP10 2202/4885PARP11 1785/4885KDM1A 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.